NCLifeSci Blog

This is your blog intro text. 

Blog News

NCBIO forum offers guidance on creating new lab space
News,
NCBIO forum offers guidance on creating new lab space

When it comes to creating lab space for a new or established business, getting your team together early and allowing plenty of time to plan are the keys to success, according to panelists assembled for NCBIO’s Lab Space Forum held online Tuesday, July 13. The pandemic has caused... Continue Reading

Date posted07/15/2021


Laura Gunter named new NCBIO president
News,
Laura Gunter named new NCBIO president

Laura Gunter Laura Gunter, M.B.A, has been selected as the new president of NCBIO, the N.C. Biosciences Organization, succeeding longtime president Sam Taylor who died in February. Gunter has served as the organization’s executive vice president since 2020 and has filled the executive... Continue Reading

Date posted07/8/2021


BIO: How the PASTEUR Act would support antibiotic R&D
Blog,
BIO: How the PASTEUR Act would support antibiotic R&D

BIO: How the PASTEUR Act would support antibiotic R&D The PASTEUR Act, legislation designed to make research and development of new antibiotics economically viable, was reintroduced in Congress last week with bipartisan support. Here’s what it would do and why it... Continue Reading

Date posted06/22/2021


Government price fixing for U.S. medicines will cost lives, jobs, innovation
Blog,
Government price fixing for U.S. medicines will cost lives, jobs, innovation

Government price fixing for U.S. medicines will cost lives, jobs, innovation Legislation that fixes prices for prescription medicines would limit patients’ access to new treatments while doing nothing to lower prices at the pharmacy counter, according to a new analysis released by... Continue Reading

Date posted05/13/2021


Vaccine patent waiver breaks faith with American companies, stifles innovation
News,
Vaccine patent waiver breaks faith with American companies, stifles innovation

Vaccine patent waiver breaks faith with American companies, stifles innovation NCBIO is extremely disappointed that the Biden administration has chosen to support waiving critical intellectual property protections for U.S. COVID-19 vaccines. This decision, known as a TRIPS waiver,... Continue Reading

Date posted05/13/2021


BIO: Why the TRIPS waiver wouldn’t work
Blog,
BIO: Why the TRIPS waiver wouldn’t work

BIO President and CEO Michelle McMurry-Heath, M.D., Ph.D., sent a letter April 19 to U.S. Trade Representative Ambassador Katherine Tai to explain why the WTO’s proposed “TRIPS waiver” would have global health and economic consequences as the pandemic rages on. India, South... Continue Reading

Date posted04/20/2021


Executive order on drug prices does no favors for NC patients, hospitals
Blog,
Executive order on drug prices does no favors for NC patients, hospitals

A new executive order from the Trump administration that slashes Medicare payments to hospitals and physicians for certain medicines will hurt patients’ access to care and financially stress already overburdened hospitals and innovation-based pharmaceutical companies, according to NCBIO, the... Continue Reading

Date posted11/25/2020